207 related articles for article (PubMed ID: 26932932)
1. Overspending driven by oversized single dose vials of cancer drugs.
Bach PB; Conti RM; Muller RJ; Schnorr GC; Saltz LB
BMJ; 2016 Feb; 352():i788. PubMed ID: 26932932
[No Abstract] [Full Text] [Related]
2. The drug industry can help reduce cancer drug costs.
Gilbar PJ; Tannock MJ
BMJ; 2016 Mar; 352():i1551. PubMed ID: 27001595
[No Abstract] [Full Text] [Related]
3. In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs.
Tefferi A; Kantarjian H; Rajkumar SV; Baker LH; Abkowitz JL; Adamson JW; Advani RH; Allison J; Antman KH; Bast RC; Bennett JM; Benz EJ; Berliner N; Bertino J; Bhatia R; Bhatia S; Bhojwani D; Blanke CD; Bloomfield CD; Bosserman L; Broxmeyer HE; Byrd JC; Cabanillas F; Canellos GP; Chabner BA; Chanan-Khan A; Cheson B; Clarkson B; Cohn SL; Colon-Otero G; Cortes J; Coutre S; Cristofanilli M; Curran WJ; Daley GQ; DeAngelo DJ; Deeg HJ; Einhorn LH; Erba HP; Esteva FJ; Estey E; Fidler IJ; Foran J; Forman S; Freireich E; Fuchs C; George JN; Gertz MA; Giralt S; Golomb H; Greenberg P; Gutterman J; Handin RI; Hellman S; Hoff PM; Hoffman R; Hong WK; Horowitz M; Hortobagyi GN; Hudis C; Issa JP; Johnson BE; Kantoff PW; Kaushansky K; Khayat D; Khuri FR; Kipps TJ; Kripke M; Kyle RA; Larson RA; Lawrence TS; Levine R; Link MP; Lippman SM; Lonial S; Lyman GH; Markman M; Mendelsohn J; Meropol NJ; Messinger Y; Mulvey TM; O'Brien S; Perez-Soler R; Pollock R; Prchal J; Press O; Radich J; Rai K; Rosenberg SA; Rowe JM; Rugo H; Runowicz CD; Sandmaier BM; Saven A; Schafer AI; Schiffer C; Sekeres MA; Silver RT; Siu LL; Steensma DP; Stewart FM; Stock W; Stone R; Storb R; Strong LC; Tallman MS; Thompson M; Ueno NT; Van Etten RA; Vose JM; Wiernik PH; Winer EP; Younes A; Zelenetz AD; LeMaistre CA
Mayo Clin Proc; 2015 Aug; 90(8):996-1000. PubMed ID: 26211600
[No Abstract] [Full Text] [Related]
4. Review of Current Policy Strategies to Reduce US Cancer Drug Costs.
Green AK; Ohn JA; Bach PB
J Clin Oncol; 2020 Feb; 38(4):372-379. PubMed ID: 31804856
[No Abstract] [Full Text] [Related]
5. Specialty medications: traditional and novel tools can address rising spending on these costly drugs.
Lotvin AM; Shrank WH; Singh SC; Falit BP; Brennan TA
Health Aff (Millwood); 2014 Oct; 33(10):1736-44. PubMed ID: 25288417
[TBL] [Abstract][Full Text] [Related]
6. Your Money or Your Life - The High Cost of Cancer Drugs under Medicare Part D.
Dusetzina SB
N Engl J Med; 2022 Jun; 386(23):2164-2167. PubMed ID: 35507526
[No Abstract] [Full Text] [Related]
7. News feature: Costly US anticancer drugs pose problems for doctors and patients.
Charatan F
BMJ; 2008 Jul; 337(7662):a778. PubMed ID: 18625596
[TBL] [Abstract][Full Text] [Related]
8. Pharmacy team involvement in navigating the revenue cycle for high-cost medications in patients with cancer.
Shank BR; Nguyen PAA; Pherson EC
Am J Manag Care; 2017 Oct; 23(12 Spec No.):SP470-SP473. PubMed ID: 29087665
[No Abstract] [Full Text] [Related]
9. Medicare cost containment strategy targets several oncology drugs.
Twombly R
J Natl Cancer Inst; 2004 Sep; 96(17):1268-70. PubMed ID: 15339960
[No Abstract] [Full Text] [Related]
10. Three Steps Toward a More Sustainable Path for Targeted Cancer Drugs.
Bekelman JE; Joffe S
JAMA; 2018 Jun; 319(21):2167-2168. PubMed ID: 29710240
[No Abstract] [Full Text] [Related]
11. Rising Cost of Anticancer Medications in the United States.
Jackson K; Nahata MC
Ann Pharmacother; 2017 Aug; 51(8):706-710. PubMed ID: 28707550
[TBL] [Abstract][Full Text] [Related]
12. Oncology drug pricing structure is broken.
Hutchinson L
Nat Rev Clin Oncol; 2015 Sep; 12(9):499. PubMed ID: 26309071
[No Abstract] [Full Text] [Related]
13. Drug wastage and costs to the healthcare system in the care of patients with non-small cell lung cancer in the United States.
Hess LM; Cui ZL; Li XI; Oton AB; Shortenhaus S; Watson IA
J Med Econ; 2018 Aug; 21(8):755-761. PubMed ID: 29673274
[TBL] [Abstract][Full Text] [Related]
14. Can treatment costs be tamed?
Malakoff D
Science; 2011 Mar; 331(6024):1545-7. PubMed ID: 21436438
[No Abstract] [Full Text] [Related]
15. The UK Cancer Drugs Fund Experiment and the US Cancer Drug Cost Problem: Bearing the Cost of Cancer Drugs Until It Is Unbearable.
Prasad V; Mailankody S
Mayo Clin Proc; 2016 Jun; 91(6):707-12. PubMed ID: 27261866
[No Abstract] [Full Text] [Related]
16. Implications of Proposed Medicare Reforms to Counteract High Cancer Drug Prices.
Mailankody S; Prasad V
JAMA; 2016 Jul; 316(3):271-2. PubMed ID: 27149663
[No Abstract] [Full Text] [Related]
17. Opportunities to significantly reduce expenditure associated with cancer drugs.
Gilbar PJ; Chambers CR; Gilbar EC
Future Oncol; 2017 Jun; 13(15):1311-1322. PubMed ID: 28589775
[TBL] [Abstract][Full Text] [Related]
18. Oncology drug costs-the imaginary crisis?
Turck R
Ann Oncol; 2017 Feb; 28(2):427-431. PubMed ID: 27771612
[No Abstract] [Full Text] [Related]
19. Monthly and Median Costs of Cancer Drugs at the Time of FDA Approval 1965-2016.
J Natl Cancer Inst; 2017 Aug; 109(8):. PubMed ID: 29117395
[No Abstract] [Full Text] [Related]
20. Lowering the High Cost of Cancer Drugs--I.
Braillon A
Mayo Clin Proc; 2016 Mar; 91(3):397. PubMed ID: 26944245
[No Abstract] [Full Text] [Related]
[Next] [New Search]
